Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Satoru Taguchi, Taketo Kawai, Sebastiano Buti, Melissa Bersanelli, Yukari Uemura, Kenjiro Kishitani, Jimpei Miyakawa, Kazuma Sugimoto, Yu Nakamura, Fusako Niimi, Tomoyuki Kaneko, Jun Kamei, Daisuke Obinata, Kenya Yamaguchi, Shigenori Kakutani, Koichiro Kanazawa, Yuriko Sugihara, Mayuko Tokunaga, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Yutaka Enomoto, Hiroaki Nishimatsu, Tetsuya Fujimura, Hiroshi Fukuhara, Tohru Nakagawa, Satoru Takahashi & Haruki Kume. (2023) Validation of a Drug-Based Score in Advanced Urothelial Carcinoma Treated with Pembrolizumab. Immunotherapy 15:11, pages 827-837.
Read now
Read now
Sebastiano Buti, Chiara Ciccarese, Daniele Zanoni, Matteo Santoni, Alessandra Modena, Francesca Maines, Annalisa Gilli, Emilio Bria, Matteo Brunelli, Anita Rimanti, Stefano Cascinu, Andrea Ardizzoni, Giampaolo Tortora & Francesco Massari. (2015) Prognostic and Predictive Factors in Patients Treated with Chemotherapy for Advanced Urothelial Cancer: Where Do We Stand?. Future Oncology 11:1, pages 107-119.
Read now
Read now
Articles from other publishers (16)
Tetsuya Shindo, Kohei Hashimoto, Keiko Fujino, Atsushi Takahashi, Hiroshi Hotta, Toshihiro Maeda, Yasuharu Kunishima, Fumimasa Fukuta, Naoki Ito, Atsushi Wanifuchi, Ryuichi Kato, Manabu Okada, Masanori Matsukawa, Hiroki Horita, Akio Takayanagi, Ko Kobayashi, Toshiaki Tanaka & Naoya Masumori. (2024) Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era. World Journal of Urology 42:1.
Crossref
Crossref
Satoru Taguchi, Taketo Kawai, Tohru Nakagawa & Haruki Kume. (2024) Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review. Japanese Journal of Clinical Oncology 54:3, pages 254-264.
Crossref
Crossref
Satoru Taguchi, Taketo Kawai, Tohru Nakagawa, Jimpei Miyakawa, Kenjiro Kishitani, Kazuma Sugimoto, Yu Nakamura, Jun Kamei, Daisuke Obinata, Kenya Yamaguchi, Tomoyuki Kaneko, Kanae Yoshida, Sachi Yamamoto, Shigenori Kakutani, Koichiro Kanazawa, Yuriko Sugihara, Mayuko Tokunaga, Akihiko Matsumoto, Yukari Uemura, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Yutaka Enomoto, Hiroaki Nishimatsu, Akira Ishikawa, Yoshinori Tanaka, Yasushi Nagase, Tetsuya Fujimura, Hiroshi Fukuhara, Satoru Takahashi & Haruki Kume. (2022) Improved survival in real‐world patients with advanced urothelial carcinoma: A multicenter propensity score‐matched cohort study comparing a period before the introduction of pembrolizumab (2003–2011) and a more recent period (2016–2020). International Journal of Urology 29:12, pages 1462-1469.
Crossref
Crossref
Youngeun Yoo, Junghye Lee, Heae Surng Park, Min-Sun Cho, Sun Hee Sung, Sanghui Park & Euno Choi. (2021) Histologically confirmed distant metastatic urothelial carcinoma from the urinary bladder: a retrospective review of one institution’s 20-year experience. Journal of Pathology and Translational Medicine 55:2, pages 94-101.
Crossref
Crossref
Diego Teyssonneau, Amaury Daste, Vincent Dousset, Jean-Luc Hoepffner, Alain Ravaud & Marine Gross-Goupil. (2017) Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response. BMC Cancer 17:1.
Crossref
Crossref
Guilhem Roubaud, Véronique Brouste, Phillipe Beuzeboc, Aude Fléchon, Diego Tosi, Sandrine Lavau-Denes, Christine Chevreau, Stéphane Culine, Stéphane Oudard, Amandine Quivy, Philippe Pourquier & Nadine Houédé. (2015) Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients. Journal of Negative Results in BioMedicine 14:1.
Crossref
Crossref
Said Abdallah Al-Mamari & Salim Said Al-Busaidy. 2015. Urological Cancer Management. Urological Cancer Management
81
98
.
Daniel Castellano, Javier Puente, Guillermo de Velasco, Isabel Chirivella, Pilar López-Criado, Nicolás Mohedano, Ovidio Fernández, Icíar García-Carbonero, María Belén González & Enrique Grande. (2014) Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer 14:1.
Crossref
Crossref
C. Pfister, M. Roupret, Y. Neuzillet, S. Larré, G. Pignot, H. Quintens, N. Houedé, E. Compérat, P. Colin, C. Roy, J.-L. Davin, L. Guy, J. Irani, T. Lebret, P. Coloby & M. Soulié. (2013) Recommandations en onco-urologie 2013 du CCAFU : Tumeurs de la vessie. Progrès en Urologie 23, pages S105-S125.
Crossref
Crossref
J. Bellmunt, R. Fougeray, J.E. Rosenberg, H. von der Maase, F.A. Schutz, Y. Salhi, S. Culine & T.K. Choueiri. (2013) Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Annals of Oncology 24:6, pages 1466-1472.
Crossref
Crossref
Andrea B. Apolo, Irina Ostrovnaya, Susan Halabi, Alexia Iasonos, George K. Philips, Jonathan E. Rosenberg, Jamie Riches, Eric J. Small, Matthew I. Milowsky & Dean F. Bajorin. (2013) Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy. JNCI: Journal of the National Cancer Institute 105:7, pages 499-503.
Crossref
Crossref
Iver Nordentoft, Karin Birkenkamp-Demtroder, Mads Agerbæk, Dan Theodorescu, Marie Stampe Ostenfeld, Arndt Hartmann, Michael Borre, Torben F Ørntoft & Lars Dyrskjøt. (2012) miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Medical Genomics 5:1.
Crossref
Crossref
J Ishioka, K Saito, M Sakura, M Yokoyama, Y Matsuoka, N Numao, F Koga, H Masuda, Y Fujii, S Kawakami & K Kihara. (2012) Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis. British Journal of Cancer 107:7, pages 1031-1036.
Crossref
Crossref
Daniel Castellano, Joan Carles, Emilio Esteban, José Manuel Trigo, Miguel Ángel Climent, José Pablo Maroto, Xavier García del Muro, Albert Font, Luis Paz-Ares, José Ángel Arranz & Joaquim Bellmunt. (2012) Recommendations for the optimal management of early and advanced urothelial carcinoma. Cancer Treatment Reviews 38:5, pages 431-441.
Crossref
Crossref
C. Pfister, M. Roupret, H. Wallerand, J.-L. Davin, H. Quintens, L. Guy, N. Houede, S. Bernardini, S. Larré, C. Mazerolles, C. Roy, D. Amsellem, F. Saint, J. Irani & M. Soulié. (2010) Recommandations en Onco-Urologie 2010 : Tumeurs urothéliales. Progrès en Urologie 20, pages S255-S274.
Crossref
Crossref
Joaquim BellmuntToni K. ChoueiriRonan FougerayFabio A.B. SchutzYacine SalhiEric WinquistStéphane CulineHans von der MaaseDavid J. VaughnJonathan E. Rosenberg. (2010) Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens. Journal of Clinical Oncology 28:11, pages 1850-1855.
Crossref
Crossref